Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus

Insulin-like growth factor I and risk of epithelial invasive ovarian cancer by tumour characteristics: results from the EPIC cohort

(2014) J Ose et al.   BRITISH JOURNAL OF CANCER

Human Insulin Does Not Increase Bladder Cancer Risk

(2014) Chin-Hsiao Tseng   PLoS One

Rosiglitazone may reduce thyroid cancer risk in patients with type 2 diabetes

(2013) Chin-Hsiao Tseng   ANNALS OF MEDICINE

Anthropometric measures and epithelial ovarian cancer risk among Chinese women: results from the Shanghai Women’s Health Study

(2013) X Ma et al.   BRITISH JOURNAL OF CANCER

Pioglitazone does not affect the risk of ovarian cancer: Analysis of a nationwide reimbursement database in Taiwan

(2013) Chin-Hsiao Tseng   GYNECOLOGIC ONCOLOGY

An international assessment of ovarian cancer incidence and mortality

(2013) Kimberly A. Lowe et al.   GYNECOLOGIC ONCOLOGY

The Effects of Metformin on Ovarian Cancer

(2013) Piyemeth Dilokthornsakul et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review

(2013) Monica Franciosi et al.   PLoS One

Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer

(2013) Faruk Tas et al.   TUMOR BIOLOGY

Suppression of cellular invasion by glybenclamide through inhibited secretion of platelet-derived growth factor in ovarian clear cell carcinoma ES-2 cells

(2012) Tamami Yasukagawa et al.   FEBS LETTERS

Metformin targets ovarian cancer stem cells in vitro and in vivo

(2012) Jessica J. Shank et al.   GYNECOLOGIC ONCOLOGY

The Antidiabetic Drug Metformin Inhibits Gastric Cancer Cell Proliferation In Vitro and In Vivo

(2012) K. Kato et al.   MOLECULAR CANCER THERAPEUTICS

Pioglitazone and Bladder Cancer: A population-based study of Taiwanese

(2011) C.-H. Tseng   DIABETES CARE

Induction of apoptosis by metformin in epithelial ovarian cancer: Involvement of the Bcl-2 family proteins

(2011) Amber Yasmeen et al.   GYNECOLOGIC ONCOLOGY

Use of metformin and the risk of ovarian cancer: A case–control analysis

(2011) Michael Bodmer et al.   GYNECOLOGIC ONCOLOGY

Use of sulphonylurea and cancer in type 2 diabetes—The Hong Kong Diabetes Registry

(2010) Xilin Yang et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials

(2010) P. D. Home et al.   DIABETOLOGIA

Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies

(2010) B. H. Ch. Stricker et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Synthesis and antitumor evaluation of novel cyclic arylsulfonylureas: ADME-T and pharmacophore prediction

(2010) Ibrahim M. El-Deeb et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort

(2010) Dorothee M. Baur et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner

(2009) R. Rattan et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Bias: Considerations for research practice

(2008) T. Gerhard   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

In vitro metformin anti-neoplastic activity in epithelial ovarian cancer

(2008) Walter H. Gotlieb et al.   GYNECOLOGIC ONCOLOGY

Sporadic Epithelial Ovarian Cancer: Clinical Relevance of BRCA1 Inhibition in the DNA Damage and Repair Pathway

(2008) Johanne I. Weberpals et al.   JOURNAL OF CLINICAL ONCOLOGY